Iambic Therapeutics, Inc. filed an amended and restated certificate of incorporation with the Secretary of State of Delaware on October 16, 2026. The filing was made in connection with the completion of the company's initial public offering (IPO). The Restated Certificate is described in the final prospectus filed with the Securities and Exchange Commission on October 15, 2026, pursuant to Rule 424(b) under the Securities Act of 1933. The filing includes the full text of the Restated Certificate as Exhibit 3.1.
Separately, the company adopted amended and restated bylaws on the same date. A description of these Restated Bylaws is also included in the final prospectus. The full text of the Restated Bylaws is filed as Exhibit 3.2 with this report.
The registrant, Iambic Therapeutics, Inc., is a Delaware corporation with its principal executive offices located at 5627 Oberlin Drive, Suite 120, San Diego, California 92121. The company’s common stock trades on The Nasdaq Stock Market LLC under the symbol IAM. The company is classified as an emerging growth company.
